Superantigens in human disease

Journal of Clinical Immunology

Volumn 19, Issue 3, 1999, Pages 149-157

  Bernal, Alejandro ^a   Proft, Thomas ^b   Fraser, John D ^b   Posnett, David N ^a  

^a Weill Cornell Graduate School of Biomedical Sciences   (United States)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Human disease; Superantigens

Indexed keywords

CYCLOOXYGENASE 2; CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN E2; SUPERANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; IMMUNOLOGY; MOUSE MAMMARY TUMOR ONCOVIRUS; PATHOGENESIS; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; T LYMPHOCYTE; TOXIC SHOCK SYNDROME; VASCULITIS; VIRUS INFECTION;

EID: 0033060443     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020547509410     Document Type: Article

References (83)

1. Bohach GA, Fast DJ, Nelson RD, Schlievert PM: Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses. Crit Rev Microbiol 17:251-272, 1990
2. Roll O, Fleischer B: A superantigen as virulence factor in an acute bacterial infection. J Infect Dis 169:1142-1146, 1994
3. Held W, Waanders GA, Shukhov AN, Scarpellino L, Acha-Orbea H, MacDonald HR: Superantigen-induced immune stimulation amplifies mouse mammary tumor virus infection and allows virus transmission. Cell 74:529-540, 1993
4. Ross SR: Mouse mammary tumor virus and its interaction with the immune system. Immunol Res 17:209-216, 1998
5. White J, Herman A, Pullen AM, Kubo R, Kappler JW, Marrack P: The Vb-specific superantigen staphylococcal enterotoxin B: Stimulation of mature T cells and clonal deletion in neonatal mice. Cell 57:27-35, 1989
6. Festenstein H: Immunogenetic and biological aspects of in vitro lymphocyte allotransformation (MLR) in the mouse. Transplant Rev 15:62-88, 1973
7. Langford MP, Stanton GJ, Johnson HM: Biological effects of staphylococcal enterotoxin A on human peripheral lymphocytes. Infect Immun 22:62-68, 1978
8. Proft T, Moffatt SL, Berkhan CJ, Fraser JD: Identification and characterization of novel superantigens from Streptococcus pyogenes. J Exp Med 189:89-101, 1999
9. Mehindate K, Thibodeau J, Dohlsten M, Kalland T, Sekaly RP, Mourad W: Cross-linking of major histocompatibility complex class II molecules by staphylococcal enterotoxin A superantigen is a requirement for inflammatory cytokine gene expression. J Exp Med 182;1573-1577, 1995
10. Chatila T, Geha RS: Signal transduction by microbial superantigens via MHC class II molecules. Immunol Rev 131:43-60, 1993
11. Thibodeau J, Cloutier I, Lavoie PM, et al.: Subsets of HLA-DR1 molecules defined by SEB and TSST-1 binding. Science 266: 1874-1878, 1994
12. Yagi J, Nakala M, Uchiyama T, et al.: Superantigen like properties of an antibody bispecific for MHC class II molecules and the V beta domain of the T cell antigen receptor. J Immunol 152:3833-3841, 1994
13. Ratcliffe MJ, Coggeshall KM, Newell MK, Julius MH: T cell receptor aggregation, but not dimerization, induces increased cytosolic calcium concentrations and reveals a lack of stable association between CD4 and the T cell receptor. J Immunol 148:1643-1651, 1992
14. Currier JR, Yassai M, Robinson MA, Gorski J: Molecular defects in TCRBV genes preclude thymic selection and limit the expressed TCR repertoire. J Immunol 157;170-175, 1996
15. Wei S, Charmley P, Robinson MA, Concannon P: The extent of the human germline T-cell receptor V beta gene segment repertoire. Immunogenetics 40:27-36, 1994
16. Levinson AI, Kozlowski LM: B-cell superantigens and their biological implications. In: Superantigens: Molecular Biology, Immunology and Relevance to Human Disease, DYM Leung, BT Huber, PM Schlievert (eds). New York, Marcel Dekker, 1997, p 405
17. Zabriskie JB: The role of temperate bacteriophage in the production of erythrogenic toxin by group A streptococci. J Exp Med 119:761, 1964
18. Fleischer B, Necker A, Leget C, Malissen B, Romagne F: Reactivity of mouse T-cell hybridomas expressing human Vbeta gene segments with staphylococcal and streptococcal superantigens. Infect Immun 64:987-994, 1996
19. Fleischer B, Bailey CJ: Recombinant epidermolytic (exfoliative) toxin A of Staphylococcus aureus is not a superantigen. Med Microbiol Immunol (Berl) 180:273-278, 1992
20. Fleischer B, Hartwig U: T lymphocyte stimulation by microbial superantigens. In Biological Significance of Superantigens, B Fleischer (ed). Basel, Karger, 1992, p 36
21. Conrad B, Weissmahr RN, Boni J, Arcari R, Schupbach J, Mach B: A human endogenous retroviral superantigen as candidate autoimmune gene in type I diabetes. Cell 90:303-313, 1997
22. Huang Z, Vafai A, Lee J, Mahalingam R, Hayward AR: Specific lysis of targets expressing varicella-zoster virus gp1 or gp1V by CD4+ human T-cell clones. J Virol 66:2604-2669, 1992
23. Oxman MN: Immunization to reduce the frequency and severity of herpes zoster and its complicalions. Neurology 45:S41-S46, 1995
24. Nader S, Bergen R, Sharp M, Arvin AM: Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. J Infect Dis 171:13-17, 1995
25. McCormack JE, Callahan JE, Kappler J, Marrack PC: Profound deletion of mature T cells in vivo by chronic exposure to exogenous superantigen. J Immunol 150:3785-3792, 1993
26. Kotzin BL, Leung D, Kappler J, Marrack P: Superantigens and their potential role in human disease. Adv Immunol 54:99-166, 1993
27. Choi Y, Lafferty JA, Clements JR, et al.: Selective expansion of T cells expressing Vb2 in toxic shock syndrome. J Exp Med 172:981-984, 1990
28. Watanabe-Ohnishi R, Low DE, McGeer A, et al.: Selective depletion of V beta-bearing T cells in patients with severe invasive group A streptococcal infections and streptococcal toxic shock syndrome. Ontario Streptococcal Study Project [see comments]. J Infect Dis 171:74-84, 1995
29. Vella AT, McCormack JE, Linsley PS, Kappler JW, Marrack P: Lipopolysaccharide interferes with the induction of peripheral T cell death. Immunity 2:261-270, 1995
30. Vella AT, Mitchell T, Groth B, et al.: CD28 engagement and proinflammatory cytokines contribute to T cell expansion and long-term survival in vivo. J Immunol 158:4714-4720, 1997
31. Biasi G, Panozzo M, Pertile P, Mezzalira S, Facchinetti A: Mechanism underlying superantigen-induced clonal deletion of mature T lymphocytes. Int Immunol 6:983-989, 1994
32. McCormack JE, Kappler J, Marrack P: Stimulation with specific antigen can block superantigen-mediated deletion of T cells in vivo. Proc Natl Acad Sci USA 91:2086-2090, 1994
33. Jupin C, Anderson S, Damais C, Alouf JE, Parani M: Toxic shock syndrome toxin as an inducer of human tumor necrosis factors and γ-interferon. J Exp Med 167:752-761, 1988
34. Miethke T, Wahl C, Heeg K, Echtenacher B, Krammer PH, Wagner H: T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: Critical role of tumor necrosis factor. J Exp Med 175:91-98, 1992
35. Hackett SP, Stevens DL: Superantigens associated with staphylococcal and streptococcal toxic shock syndrome are potent inducers of tumor necrosis factor-beta synthesis. J Infect Dis 168:232-235, 1993
36. Miethke T, Wahl C, Regele D, Gaus H, Heeg K, Wagner H: Superantigen mediated shock: A cytokine release syndrome. Immunobiology 189:270-284, 1993
37. Bradley GS, Campbell YG, Castle RM, Grove SA: Correlation of temperature and toxicity in murine studies of staphylococcal enterotoxins and toxic shock syndrome toxin 1. Infect Immun 67:1521-1525, 1999
38. Bette M, Schafer MK H, van Rooijen N, Weihe E, Fleischer B: Distribution and kinetics of superantigen-induced cytokine gene expression in mouse spleen J Exp Med 1993; 178:1531-1540
39. Marrack P, Blackman M, Kushnir E, Kappler J: The toxicity of staphylococcal enterotoxin B in mice is mediated by T cells. J Exp Med 171:455-464, 1990
40. Miethke T, Duschek K, Wahl C, Heeg K, Wagner H: Pathogenesis of the toxic shock syndrome: T cell mediated lethal shock caused by the superantigen TSST-I. Eur J Immunol 23:1494-1500, 1993
41. Trede NS, Geha RS, Chatila T: Transcriptional activation of IL-I beta and tumor necrosis factor-alpha genes by MHC class II ligands. J Immunol 146:2310-2315, 1991
42. Abe J, Takeda T: Characterization of a superantigen produced by Yersinia Pseudotuberculosis. In Superantigens: Molecular Biology, Immunology, and Relevance to Human Disease, DYM Leung. BT Huber, PM Schlievert (eds). New York, Marcel Dekker, 1997, p 369
43. Leung DYM, Schlievert PM: Superantigens in human disease: Future directions in therapy and illucidation of disease pathogenesis. In Superantigens. DYM Leung, BT Huber, PM Schlievert (eds). New York, Marcel Dekker, 1997, p 581
44. Bouventre PF, Heeg H, Cullen C, Lian CJ: Toxicity of recombinant toxic shock syndrome toxin I and mutant toxins produced by Staphylococcus aureus in a rabbit infection model of toxic shock syndrome. Infect Immun 61:793-799, 1993
45. de Azavedo JC, Foster TJ, Hartigan PJ, et al.: Expression of the cloned toxic shock syndrome toxin 1 gene (tst) in vivo with a rabbit uterine model. Infect Immun 50:304-309, 1985
46. Tracey KJ, Beutler B, Lowry SF, et al.: Shock and tissue injury induced by recombinant human cachectin. Science 234:470-474, 1986
47. Miethke T, Wahl C, Wagner H: Role of cytokines/lymphokines in Gram-positive bacterial infections. In Human Cytokines: Their Role in Disease and Therapy, BB Aggarwal, RK Puri (eds). Cambridge, MA, Blackwell Science, 1995. p 371
48. Chapman PB, Lester TJ, Casper ES, et al.: Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol 5:1942-1951, 1987
49. Pfeffer K, Matsuyama T, Kundig TM, et al.: Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73:457-467, 1993
50. Zeinbowicz A, Vane JR: Induction of nitric oxide synthase activity by toxic shock syndrome toxin 1 in a macrophage-monocyte cell line. Proc Natl Acad Sci USA 89:2051-2055, 1992
51. MacMicking JD, Nathan C, Hom G, et al: Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase published erratum appears in Cell 1995 Jun 30;81(17): following 1170]. Cell 81:641- 650, 1995
52. Beutler B, Cerami A: The biology of cachectin/TNF - A primary mediator of the host response. Annu Rev Immunol 7:625-655, 1989
53. Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA: Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 81: 1162-1172, 1988
54. Montegut W, Lowry SF, Moldawer LL: Role of cytokines in septic shock and shock-related syndromes. In Human Cytokines: Their Role in Disease and Therapy, BB Aggarwal, RK Puri (eds). Cambridge, MA, Blackwell Science, 1995, p 381
55. Smith JW, Urba WJ, Curti BD, et al.: The toxic and hematologic effects of interleukin-1 alpha administered in a phase 1 trial to patients with advanced malignancies. J Clin Oncol 10:1141-1152, 1992
56. Beutler B, Beutler S: The pathogenesis of fever. In Cecil Textbook of Medicine, JB Wyngaarden, LH Smith, JC Bennet (eds). Philadelphia, W. B. Sounders, 1992, p 1568
57. Brysk MM, Bell T, Hoida C, Tyring SK, Rajaraman S: Interferon-gamma modulates terminal differentiation and the expression of desquamin in cultured keratinocytes. Exp Cell Res 197:140-147, 1991
58. Brysk MM, Bell T, Brysk H, Selvanayagam P, Rajaraman S: Enzymatic activity of desquamin. Exp Cell Res 214:22-26, 1994
59. Rosenberg SA, Lotze MT, Muul LM, et al.: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889-897, 1987
60. Ortho Multicenter Transplant Study Group: A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 313:337-342, 1985
61. Stevens DL: The toxic shock syndromes. Infect Dis Clin North Am 10:727-746, 1996
62. Dohlsten M, Hedlund G, Segren S, et al.: Human major histocompatibility complex class II-negative colon carcinoma cells present staphylococcal superantigens to cytotoxic T lymphocytes: Evidence for a novel enterotoxin receptor. Eur J Immunol 21:1229-1233, 1991
63. Alber G, Hammer DK, Fleischer B: Relationship between enterotoxic- and T lymphocyte-stimulating activity of staphylococcal enterotoxin B. J Immunol 144:4501-4506, 1990
64. Reck B, Scheuber PH, Londong W, Sailer-Kramer B, Bartsch K, Hammer DK: Protection against the staphylococcal enterotoxin- induced intestinal disorder in the monkey by anti-idiotypic antibodies. Proc Natl Acad Sci USA 85:3170- 3174, 1988
65. Harris TO, Grossman D, Kappler JW, Marrack P, Rich RR, Betley MJ: Lack of complete correlation between emetic and T-cell- stimulatory activities of staphylococcal enterotoxins. Infect Immun 61:3175-3183, 1993
66. Rogers TJ, Guan L, Zhang L: Characterization of an alternative superantigen binding site expressed on a renal fibroblast cell line. Int Immunol 7:1721-1727, 1995
67. Hamad ARA, Marrack P, Kappler JW: Transcytosis of staphylococcal superantigen toxins. J Exp Med 185:1447-1454, 1997
68. Lionetti P, Spencer J, Breese EJ, Murch SH, Taylor J, MacDonald TT: Activation of mucosal V beta 3 T cells and tissue damage in human small intestine by the bacterial superantigen, Staphylococcus aureus enterotoxin B. Eur J Immunol 23:664-668, 1993
69. Spiekermann GM, Nagler-Anderson C: Oral administration of the bacterial superantigen staphylococcal enterotoxin B induces activation and cytokine production by T cells in murine gut-associated lymphoid tissue. J Immunol 161;5825-5831, 1998
70. McKay DM, Benjamin MA, Lu J: CD4+ T cells mediate superantigen-induced abnormalities in murine jejunal ion transport. Am J Physiol 275:G29-G38, 1998
71. McKay DM, Singh PK: Superantigen activation of immune cells evokes epithelial (T84) transport and barrier abnormalities via IFN-gamma and TNF alpha: Inhibition of increased permeability, but not diminished secretory responses by TGF-beta2. J Immunol 159:2382-2390, 1997
72. Chapman PB, Kolitz JE, Hakes TB, et al.: A phase 1 trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma. Invest New Drugs 6:179-188, 1988
73. Ohmen JD, Barnes PF, Grisso CL, Bloom BR, Modlin RL: Evidence for a superantigen in human tuberculosis. Immunity 1:35-43, 1994
74. Cohen-Tervaert JW, Popa ER, Bos NA: The role of superantigens in vasculitis. Curr Opin Rheumatol 11:24-33, 1999
75. Leung DY, Travers JB, Giorno R, et al.: Evidence for a streptococcal superantigen-driven princess in acute gullate psoriasis. J Clin Invest 96:2106-2112, 1995
76. Valdimarsson H, Baker BS, Jonsdottir I, Powles A, Fry L: Psoriasis: A T-cell-mediated autoimmune disease induced by streptococcal superantigens? [see comments]. Immunol Today 16:145-149, 1995
77. Dohrescu D, Ursea B, Pope M, Asch AS, Posnett DN: Enhanced HIV-1 replication in Vb12 T cells due to human cytomegalovirus in monocytes: Evidence for a putative herpesvirus superantigen. Cell 82:753-763, 1995
78. Sutkowski N, Palkama T, Ciurli C, Sekaly R-P, Thorley-Lawson DA, Huber BT: An Epstein-Barr virus associated superantigen. J Exp Med 184:971-980, 1996
79. Posnett DN: Viral superantigens in humans. A potential role in HIV and CMV infection. In Superantigens: Structure, Biology and Relevance to Human Disease, DYM Leung, B Huber, P Schlievert (eds). New York, Marcel Dekker, 1997, p 503
80. Lafon M: Superantigen in rabies virus and its involvement in paralysis. In Superantigens, DYM Leung, B Huber, P Schlievert (eds). New York, Marcel Dekker, 1997, p 85
81. Tsiagbe VK, Asakawa J, Miranda A, Sutherland RM, Paterson Y, Thorbecke GJ: Syngeneic response to SJL follicular center B cell lymphoma (reticular cell sarcoma) cells is primarily in V bela 16 + CD4+ T cells. J Immunol 150:5519-5528, 1993
82. Tsiagbe VK, Yoshimoto T, Asakawa J, Cho SY, Meruelo D, Thorbecke GJ: Linkage of superantigen-like stimulation of syngeneic T cells in a mouse model of follicular center B cell lymphoma to transcription of endogenous mammary tumor virus. EMBO J 12:2313-2320, 1993
83. Monday SR, Vath GM, Witold AF, et al.: Unique superantigen activity of staphylococcal exfoliative toxins. J Immunolo 162: 4550-4559, 1999